



COMPANY OVERVIEW

By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.

RECENT NEWS

ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX

Sep 28 2018, 7:00 AM EDT

Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy

Sep 5 2018, 7:00 AM EDT

ITUS Corporation to Present at Next Generation Dx Summit

Aug 17 2018, 7:00 AM EDT

STOCK OVERVIEW

Symbol	ITUS
Exchange	Nasdaq
Market Cap	88.43m
Last Price	\$4.73
52-Week Range	\$1.83 - \$6.43

INVESTOR RELATIONS

Mike Catelani
Chief Operating Officer & Chief
Financial Officer
T: 408-708-9808

MANAGEMENT TEAM

Dr. Amit Kumar, Ph.D

Chairman, President & Chief Executive Officer

Michael Catelani

Chief Operating Officer and Chief Financial Officer

John Roop

Senior Vice President of Engineering

Anthony Campisi

Vice President of Engineering

ANIXA BIOSCIENCES, INC.

3150 Almaden Expressway
Suite 250
San Jose, CA 95118
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.